Primex News International

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Eternal Bright Marks 10 Years With A Fresh Identity And The Same Trusted Formulas

    July 12, 2025

    From Jobs to Juggernauts: PM Modi’s Rozgar Mela Is a Masterclass in Economic Optics

    July 12, 2025

    How to Become an Authorized Person with SMC: Know the Eligibility and Key Benefits

    July 12, 2025
    Facebook Twitter Instagram
    Primex News International
    • Home
    Facebook Twitter Instagram
    Primex News International
    Home»Health»IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India
    Health

    IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India

    By August 17, 2024No Comments2 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email

    Mumbai (Maharashtra) [India], August 16: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030.

    In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

    The launch event was graced by esteemed personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek, Sri Sunil Ghai, and Sri. Supreet Deshpande.

    During phase 3 trials in India, Diulcus demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.

    Mr. Premchand Godha, Executive Chairman of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, “With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical need and its focus on the diabetes therapy.”

    Diulcus will be made available to the patients of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

    Disclaimer: The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Health
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Protyze Launches HYDRA-X: India’s An Advanced Clear Protein with Electrolytes, Creatine & Glutamine.

    July 11, 2025

    Celebrities Who Swear by Cranberries – Here’s Why

    July 10, 2025

    Why Skinimalism Is More Than a Trend: Dr. Jagdish Sakhiya on the New Face of Skincare

    July 8, 2025

    Doctor’s Day Special: Recognizing the Early Signs of Osteoarthritis

    July 2, 2025

    Fredun Pharmaceuticals Enters Pet Care Market with Strategic Acquisition of One Pet Stop

    July 2, 2025

    Protyze Launches Hydra Clear Whey Protein: India’s First Protein-Electrolyte Functional Protein Drink

    July 1, 2025

    Comments are closed.

    Top Reviews
    Editors Picks

    Eternal Bright Marks 10 Years With A Fresh Identity And The Same Trusted Formulas

    July 12, 2025

    From Jobs to Juggernauts: PM Modi’s Rozgar Mela Is a Masterclass in Economic Optics

    July 12, 2025

    How to Become an Authorized Person with SMC: Know the Eligibility and Key Benefits

    July 12, 2025

    Packman Engineering: Delivering End-to-End Packaging Solutions with Indian Expertise and Global Vision

    July 12, 2025
    About Us
    About Us
    Our Picks

    Eternal Bright Marks 10 Years With A Fresh Identity And The Same Trusted Formulas

    July 12, 2025

    From Jobs to Juggernauts: PM Modi’s Rozgar Mela Is a Masterclass in Economic Optics

    July 12, 2025

    How to Become an Authorized Person with SMC: Know the Eligibility and Key Benefits

    July 12, 2025
    Top Reviews
    © 2025 Primex News International. Designed by Primex Media Services.
    • Home

    Type above and press Enter to search. Press Esc to cancel.